Weight Loss Drugs Take Center Stage at 2025 American Diabetes Association Meeting

‘Weight loss medication’ a New Trend in the Healthcare Market

Announcement

At the American Diabetes Association’s annual meeting, the need for new weight-loss medicines, primarily for muscle preservation and showing fewer side effects, was the center of concern. The topic entered the discussion all of a sudden and took the limelight of the meeting. At the recent scientific sessions of the American diabetes association 2025, analysts and companies shared their concerns and views regarding health issues and medicines, keeping weight loss and obesity at the center of the discussion.

Eli Lilly and Novo Nordisk a potential weight loss leaders, have given updates on orforglipron and Cagrisema. These medications have proven as a success for the company’s recent franchises. At the meeting, the key player companies introduced new possibilities through their respective exceptional presentation. The presentation follows, Innovent on its GLP-1/glucagon dual agonist mazdutide and Amgen on its GLP-1/GIP analog maritide.

Highlights

Eli Lilly’s oral GLP-1 agonist orforglipron, a recent phase 3 cleared drug, was the highlight of the meeting. The presentation showed injectable-like efficacy, which is considered for the third quarter for obesity. The mid-stage antibody, pharma’s bimagrumab, aims to engage myostatin/activin type 2 receptors are engaged in initiate cascades that prevent growth. The bimagrumab prevents muscle loss and doubles the muscle mass. Lily’s data from its phase 2b ‘the believe trial’ at ADA represents bimagrumab’s its effectivity. When bimagrumab and GLP-1 drug Wegovy (semaglutide) are used together, it can reduce weight by 22.1% at 72 weeks. The 92.8% of this weight loss is considered to be fat loss by 7% which is due to the loss of lean mass. Overall, the data is the right choice for next-generation weight loss treatment.

Other Efforts

The amylin, a novo-centric pancreatic peptide that reduces blood sugar levels and subdues appetite, is also a contestant in the weight loss space. The cagrisema, a merger regimen including semaglutide and amylin mimetic cagrilintide, is ahead in Nova’s study. Zealand Pharma is looking for an advancement in the current GLP-1 for obesity by including a molecular cousin, a mix of GLP-2. Similar to Lily, the scholar rock is also putting efforts to enhance the quality of medication regarding weight loss. Whereas, TERN-501, a Terns Pharmaceuticals agonist, is a vital regulator of various metabolic processes.

These efforts and changes to the medication and discoveries through studies are a revolutionary attempt for the next generation of weight loss medications.